1. Home
  2. COEP vs YI Comparison

COEP vs YI Comparison

Compare COEP & YI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Coeptis Therapeutics Holdings Inc.

COEP

Coeptis Therapeutics Holdings Inc.

HOLD

Current Price

$15.13

Market Cap

100.4M

Sector

Health Care

ML Signal

HOLD

Logo 111 Inc.

YI

111 Inc.

HOLD

Current Price

$3.61

Market Cap

38.1M

ML Signal

HOLD

Company Overview

Basic Information
Metric
COEP
YI
Founded
2017
2010
Country
United States
China
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Retail-Drug Stores and Proprietary Stores
Sector
Health Care
Consumer Staples
Exchange
Nasdaq
Nasdaq
Market Cap
100.4M
38.1M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
COEP
YI
Price
$15.13
$3.61
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
91.6K
13.5K
Earning Date
11-14-2025
12-05-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$500,996.00
$1,979,883,442.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.31
$3.19
52 Week High
$21.41
$11.35

Technical Indicators

Market Signals
Indicator
COEP
YI
Relative Strength Index (RSI) 45.46 40.53
Support Level $14.82 $3.32
Resistance Level $16.45 $3.94
Average True Range (ATR) 1.47 0.23
MACD -0.21 0.03
Stochastic Oscillator 4.78 51.22

Price Performance

Historical Comparison
COEP
YI

About COEP Coeptis Therapeutics Holdings Inc.

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

About YI 111 Inc.

111 Inc operates an integrated online and offline platform in the healthcare ecosystem in China, whereby the Group is engaged in the sales of medical and wellness products through online retail and wholesale pharmacies and offline retail pharmacies, as well as the provision of certain value-added services, such as online consultation services and e-prescription services to consumers in the People's Republic of China. The company has two operating segments: the B2C segment and B2B segment whereby the B2C business represents revenue generated from individual consumers while the B2B business represents revenue generated from corporate customers. It derives a majority of its revenue from the B2B segment.

Share on Social Networks: